Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Center for Research Resources (NCRR) Arthritis Foundation |
---|---|
Information provided by: | National Center for Research Resources (NCRR) |
ClinicalTrials.gov Identifier: | NCT00008749 |
Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.
Condition |
---|
Lupus Erythematosus, Systemic |
Study Type: | Observational |
Study Design: | Natural History, Case Control |
Official Title: | Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus |
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion:
A diagnosis of systemic lupus erythematosus
Contact: Randy Q Cron, MD, Ph.D. | 215-590-1844 |
United States, Pennsylvania | |
Children's Hospital of Philadelphia | Recruiting |
Philadelphia, Pennsylvania, United States, 19104-4318 | |
Contact: Randy Q Cron, M.D., Ph.D. 215-590-1844 |
Study ID Numbers: | NCRR-M01RR00240-1736 |
Study First Received: | January 16, 2001 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00008749 |
Health Authority: | United States: Federal Government |
Autoimmune Diseases Lupus Erythematosus, Systemic Connective Tissue Diseases |
Immune System Diseases |